Galectin Therapeutics Inc Stock Price, News & Analysis

Galectin Therapeutics (NASDAQ:GALT) announced five scientific presentations at The Liver Meeting™ 2022, focusing on liver cirrhosis and portal hypertension related to non-alcoholic steatohepatitis (NASH). Key topics include the prevalence of esophageal varices, the biochemical profiles of 271 NASH cirrhosis patients, and the clinical utility of the ELF score. The company aims to showcase new data on their drug candidate Belapectin, designed to inhibit the galectin-3 protein, which is involved in liver fibrosis. These findings contribute to ongoing Phase 2b/3 studies.

Galectin Therapeutics (NASDAQ: GALT) announced its participation in two upcoming conferences. On October 17, 2022, Dr. Pol F. Boudes will present at the H.C. Wainwright 6th Annual NASH Investor Conference. The second presentation will take place on October 20, 2022, at the Discovery on Target conference, focusing on belapectin, a galectin-3 inhibitor for NASH cirrhosis. Belapectin has shown promise in preclinical studies for reversing liver fibrosis. NASH affects millions in the U.S., and belapectin is under Fast Track designation for its potential treatment.

Galectin Therapeutics (NASDAQ: GALT) has filed an Investigational New Drug (IND) application with the FDA for belapectin in combination with pembrolizumab to treat head and neck cancer. The company received a 'Study May Proceed' letter for a Phase 2 trial focusing on recurrent/metastatic PD-L1 positive squamous cell carcinoma. This milestone adds to the ongoing NAVIGATE trial for NASH cirrhosis, which has seen an increase in active sites and steady enrollment progress. The potential partnership for financing the oncology program is also being explored.

Galectin Therapeutics (NASDAQ: GALT) announced positive results from its second independent Data and Safety Monitoring Board (DSMB) meeting regarding the NAVIGATE trial. This phase 2b/3 study evaluates belapectin for preventing esophageal varices in patients with NASH-related liver cirrhosis. The DSMB concluded belapectin showed a favorable safety profile, allowing the trial to proceed without changes. With 258 patients randomized and an additional 74 in screening, full enrollment is anticipated by year-end. This milestone reinforces the urgent need for new treatments for liver cirrhosis amidst rising NASH cases.

Galectin Therapeutics Inc. (NASDAQ: GALT) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. Dr. Pol F. Boudes, Chief Medical Officer, will present on September 13 at 11:00 AM ET. The company is focused on developing therapies targeting galectin proteins, particularly belapectin, for conditions like liver fibrosis and cirrhosis. Notably, belapectin shows promise in treating Non-alcoholic Steatohepatitis (NASH) and has Fast Track designation from the FDA. A live webcast of the presentation will be available on their website.

Galectin Therapeutics, Inc. (NASDAQ: GALT) reported financial results for Q2 2022, revealing a net loss of $9.7 million, or $0.16 per share, compared to a loss of $8.5 million, or $0.15 per share in Q2 2021. Major developments include securing a $60 million line of credit to fund the Phase 2b NAVIGATE trial and progress on an Investigational New Drug (IND) application for belapectin in treating recurrent head and neck cancer. The firm is on track to complete enrollment of the NAVIGATE trial by Q4 2022 and had $24.2 million in cash as of June 30, 2022.

Galectin Therapeutics (GALT) announced a $60 million unsecured line of credit with chairman Richard E. Uihlein, marking the largest financing in the company's history. The funds will cover planned expenditures through 2024 as Galectin progresses its NAVIGATE clinical trial for belapectin, aimed at treating NASH cirrhosis. The credit line allows for borrowings until July 2024 and includes provisions for converting debt into equity at no less than $3.00 per share. CEO Joel Lewis expressed gratitude for Uihlein's support, emphasizing the commitment to align shareholder interests with significant ongoing projects.

Galectin Therapeutics (NASDAQ: GALT) announced two significant scientific presentations employing artificial intelligence to analyze liver biopsies for patients with cirrhosis due to NASH. The data, from a Phase 2 study (NCT02462967), will be shared at the International Liver Congress™ 2022 in London. The first abstract discusses an AI method for detecting liver damage, while the second focuses on machine learning scores predicting portal hypertension complications. These advancements highlight the company's expertise in managing liver disease and the potential impact of belapectin, their leading drug candidate.

Galectin Therapeutics Inc. (NASDAQ: GALT) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, and the 5th Global NASH Congress in London on May 26-27, 2022. Dr. Pol F. Boudes will discuss innovations in NASH cirrhosis and clinical endpoints for NASH trials. Belapectin, Galectin's lead drug targeting galectin-3, shows promise in treating liver fibrosis and cirrhosis, with a Phase 2 study indicating potential to prevent esophageal varices in NASH patients. The NAVIGATE trial is currently enrolling patients to further investigate belapectin's efficacy.